title: Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
abstract: Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.
authors.affiliation: Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Rome, Italy. zaccarelli@inmi.it
authors.forename: Mauro
authors.initials: M
authors.lastname: Zaccarelli
authors.forename: Carlo Federico
authors.initials: CF
authors.lastname: Perno
authors.forename: Federica
authors.initials: F
authors.lastname: Forbici
authors.forename: Fabio
authors.initials: F
authors.lastname: Soldani
authors.forename: Sandro
authors.initials: S
authors.lastname: Bonfigli
authors.forename: Caterina
authors.initials: C
authors.lastname: Gori
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Trotta
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Bellocchi
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Liuzzi
authors.forename: Roberta
authors.initials: R
authors.lastname: D'Arrigo
authors.forename: Patrizio
authors.initials: P
authors.lastname: De Longis
authors.forename: Evangelo
authors.initials: E
authors.lastname: Boumis
authors.forename: Rita
authors.initials: R
authors.lastname: Bellagamba
authors.forename: Valerio
authors.initials: V
authors.lastname: Tozzi
authors.forename: Pasquale
authors.initials: P
authors.lastname: Narciso
authors.forename: Andrea
authors.initials: A
authors.lastname: Antinori
mesh_terms: D000328:Adult; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005260:Female; D005973:Glutamine / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D008715:Methionine / Q000235:genetics; D008826:Microbial Sensitivity Tests; D015999:Multivariate Analysis; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D012307:Risk Factors; D016879:Salvage Therapy
chemical_list: D018894:Reverse Transcriptase Inhibitors; D005973:Glutamine; D019259:Lamivudine; D008715:Methionine; D054303:HIV Reverse Transcriptase